Floatz logo

gc101

Adverse Drug Event

Shanghai Juncell Therapeuticsgene_therapyPhase 1/2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Adverse Drug Event cohort.

Asset / SponsorPhaseRating
Oliceridine
University of Tennessee
Phase 4BB
ERIBULIN MONOMETHANESULFONATE
Oncologia Medica dell'Ospedale Fatebenefratelli
Phase 4BB
Eloxatin
Zhejiang University
Phase 3BB
Capecitabine
Zhejiang University
Phase 3BB
Salovum
Henrik Lindman
Phase 3B

View all 9 →

Same molecule, other indications

gc101 is also rated in:

SMA - Spinal Muscular AtrophyDormant
BB
Indicative ·
66 / 100
View asset →
Tumor Infiltrating LymphocytesDormant
B
Indicative ·
59 / 100
View asset →
SafetyDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →